Aurora-Kinase-A-(Aurora-2-or-Serine/Threonine-Protein-Kinase-15-or-Serine/Threonine-Protein-Kinase-6-or-Serine/Threonine-Protein-Kinase-Aurora-A-or-Aurora/IPL1-Related-Kinase-1-or-AURKA-or-EC-2.7.11.1)-Pipeline-Review-H2-2017

Aurora-Kinase-A-(Aurora-2-or-Serine/Threonine-Protein-Kinase-15-or-Serine/Threonine-Protein-Kinase-6-or-Serine/Threonine-Protein-Kinase-Aurora-A-or-Aurora/IPL1-Related-Kinase-1-or-AURKA-or-EC-2.7.11.1)-Pipeline-Review-H2-2017


  • Products Id :- GMDHC0995TDB
  • |
  • Pages: 77
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Aurora Kinase A-Pipeline Review, H2 2017'; Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression. It plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. It is required for initial activation of CDK1 at centrosomes and normal axon formation. It phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. It regulates KIF2A tubulin depolymerase activity.

The report 'Aurora Kinase A-Pipeline Review, H2 2017' outlays comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 2 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Metastatic Breast Cancer, Neuroblastoma, Ovarian Cancer, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, Brain Tumor, Breast Cancer, Burkitt Lymphoma, Central Nervous System (CNS) Tumor, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Cutaneous Angiosarcoma, Diffuse Large B-Cell Lymphoma, Ependymoma, Follicular Lymphoma, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hepatocellular Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Nasopharyngeal Cancer, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Oligodendroglioma, Pilocytic Astrocytoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Soft Tissue Sarcoma, Subependymal Giant Cell Astrocytoma, Testicular Cancer and Waldenstrom Macroglobulinemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)

The report reviews Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Overview

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Companies Involved in Therapeutics Development

AbbVie Inc

Amgen Inc

CASI Pharmaceuticals Inc

Cielo Therapeutics Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

Sanofi

Sareum Holdings Plc

Sigma-Tau SpA

Taiho Pharmaceutical Co Ltd

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Drug Profiles

alisertib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-900-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

danusertib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENMD-2076-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilorasertib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8745-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-156497-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Aurora A Kinase for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Aurora A/B Kinase for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-5589-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-119-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TY-011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Dormant Products

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Discontinued Products

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)-Product Development Milestones

Featured News & Press Releases

May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma

May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer

Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer

Mar 28, 2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting

Aug 16, 2016: CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma

Aug 03, 2016: China and Hong Kong Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors

Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma

May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)

Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference

Nov 05, 2015: Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting

Nov 04, 2015: CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma

Oct 14, 2015: CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma

Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors

Jun 04, 2015: CASI Files New Drug Clinical Trial Application With China FDA To Expand U.S. Development Of ENMD-2076 In Fibrolamellar Carcinoma

May 12, 2015: Takeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AbbVie Inc, H2 2017

Pipeline by Amgen Inc, H2 2017

Pipeline by CASI Pharmaceuticals Inc, H2 2017

Pipeline by Cielo Therapeutics Inc, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Pipeline by Sanofi, H2 2017

Pipeline by Sareum Holdings Plc, H2 2017

Pipeline by Sigma-Tau SpA, H2 2017

Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Dormant Products, H2 2017 (Contd..3), H2 2017

Dormant Products, H2 2017 (Contd..4), H2 2017

Dormant Products, H2 2017 (Contd..5), H2 2017

Discontinued Products, H2 2017

Discontinued Products, H2 2017 (Contd..1), H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

Amgen Inc

CASI Pharmaceuticals Inc

Cielo Therapeutics Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

Sanofi

Sareum Holdings Plc

Sigma-Tau SpA

Taiho Pharmaceutical Co Ltd

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) Therapeutic Products under Development, Key Players in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) Therapeutics, Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) Pipeline Overview, Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) Pipeline, Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) Pipeline Assessment

select a license
Single User License
USD 3500 INR 241500
Site License
USD 7000 INR 483000
Corporate User License
USD 10500 INR 724500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com